Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Orphan Drugs Gain More Attention, FDA Releases Development Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

Straightforward draft document seems aimed at entities that have limited experience working with the agency.

Advertisement

Related Content

PDUFA VI: Price Tag For Patient Experience Data Validation May Go Up
In Manufacturing, Absence Of Evidence Is Not Evidence Of Absence, FDA Tells BioMarin
Biomarkers In Orphan Studies Still Need Past Experience, FDA Says
Rare Disease R&D: FDA To Use NIH Registry For Natural History Studies
Rare Diseases Need Ongoing Natural History Studies To Speed Trials, FDA Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS078807

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel